From: Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
Patient | Primary site | First surgery | Delay 1stdiagnosis / advanced disease (months) | Metastatic/Locally advanced | Treatment for advanced disease before systemic treatment | First-line treatment | PFS/OS (months) |
---|---|---|---|---|---|---|---|
1 | Pleura | R1 | 150 | Metastatic | Surgery (3) | AI | 6,9 / 22,2 |
2 | Peritoneum | R0 | 100 | Metastatic | No | AI | 14,5 / 70,8 |
3 | Pleura | R1 | 12 | Metastatic | No | AI | 5,2 / 29 |
4 | Tip | N | 0 | Locally advanced | No | PLD | 1,7 / 6,4 |
5 | Pleura | R1 | 20 | Metastatic | No | Adriamycine | 1,4 / 22,4 |
6 | Cerebellum | Unk | 128 | Metastatic | Surgery (1) | Brostallicin | 4,8 / 34,5 |
7 | Pelvic | N | 0 | Metastatic | Radiotherapy | Adriamycine | 9,3 / 32,8 |
8 | Pleura | R0 | 20 | Metastatic | Surgery (1) | AI | 2,4 / 21,2 |
9 | Mediastinum | N | 0 | Locally advanced | No | MAID | 9,1 / 12,4 |
10 | Pleura | Unk | 52 | Locally advanced | Surgery (1) | Adriamycine | 60 / 68,8 |
11 | Shoulder | R1 | 16 | Locally advanced | No | AI | 9 / 19,4 |
12 | Pelvic | R0 | 0 | Metastatic | No | Adriamycine | 1,5 / 5,7 |
13 | Pleura | R2 | 200 | Locally advanced | Surgery (1) | Adriamycine-Palifosfamide | 6,7 – 10,7 |
14 | Pelvic | R0 | 156 | Locally advanced | No | Adriamycine | 17,5 / 50,8 |
15 | Pleura | R0 | 11 | Metastatic | No | Adriamycine | 2,1 / 2,7 |
16 | Spine | Unk | 96 | Locally advanced | Surgery (1) | AI | 5,9 / 60 |
17 | Tip | N | 0 | Metastatic | No | Adriamycine | 4 / 4 |
18 | Spine | R2 | 120 | Metastatic | Surgery (1) and RT | AI | 2,9 / 32,3 |
19 | Pleura | R1 | 216 | Metastatic | Surgery (1) and RT | Adriamycine | 12,5 / 27,3 |
20 | Pleura | R1 | 12 | Locally advanced | No | Carboplatin-Paclitaxel | 1,0 / 2,1 |
21 | Bladder | R0 | 32 | Metastatic | No | Brostallicin | 1,8 / 1,9 |
22 | Pleura | R0 | 27 | Metastatic | No | Paclitaxel | 0,4 / 0,4 |
23 | Pleura | Unk | 64 | Metastatic | Surgery (2) | Vinorelbin | 5,2 / 64,5 |